Erschienen in:
01.07.2011 | Breast Oncology
Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration
verfasst von:
Jennifer L. Gnerlich, MD, Anjali D. Deshpande, PhD, MPH, Donna B. Jeffe, PhD, Susmitha Seelam, MSPH, Eric Kimbuende, MSPH, Julie A. Margenthaler, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 7/2011
Einloggen, um Zugang zu erhalten
Abstract
Background
Male breast cancer accounts for less than 1% of all breast cancers, yet males have a worse prognosis than females with breast cancer.
Methods
Using the 1988–2003 Surveillance, Epidemiology, and End Results Program data, we conducted a retrospective, population-based cohort study to investigate stage-specific differences in breast cancer-specific and all-cause mortality between males and females. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) using Cox regression models to compare breast cancer-specific and all-cause mortality by stage between males and females, controlling for potential confounding variables.
Results
There were 246,059 patients with a first, single, primary breast cancer [1,541 (0.6%) male; 244,518 (99.4%) female]. Compared with females, males were more likely to be older, Black, married, diagnosed at more advanced stages, and treated with mastectomy (each P < 0.001). Males also were more likely to have lower grade and estrogen/progesterone receptor-positive tumors (each P < 0.001). After controlling for confounders, males were more likely to die from their breast cancer when compared with females, only if diagnosed with stage I disease (aHR 1.72, CI 1.15–2.61). For all-cause mortality, males were more likely than females to die at each stage of disease except stage IV.
Conclusions
Although all-cause mortality was higher for men than women at all stages of nonmetastatic breast cancer, higher male breast cancer-specific mortality was attributed to poorer survival in stage I disease. However, this statistical difference is unlikely to be clinically relevant and attributable to in-stage migration.